X

 

We would like to inform you that Viatris, the marketing authorisation holder for Creon® has decided to increase the capsule length of Creon® 25000 from 21.7mm to 24.2mm. The diameter of the capsule will not change.

The new size of Creon® 25000 capsule does not affect the efficacy of the product and should not have an impact on the patient’s ability to swallow the capsules whole.



This page is intended for members of the public who are looking for more information.

Please find the below links to some helpful and independent information on pancreatic exocrine insufficiency.

Pancreatic Cancer UK

Pancreatic Cancer Action

Cystic Fibrosis Trust

Guts UK

Information about Creon® (pancreatin) can be found in the patient information leaflets below.

Creon Micro Pancreatin 60.12 mg Gastro-resistant Granules - Patient Information Leaflet (PIL) - (emc) (medicines.org.uk)

Creon 10000 Capsules - Patient Information Leaflet (PIL) - (emc) (medicines.org.uk)

Creon 25000 Capsules - Patient Information Leaflet (PIL) - (emc) (medicines.org.uk)


Please note, while efforts have been made to choose reputable sources, Viatris cannot take responsibility on these pages maintained by external providers.

You are leaving the Creon® patient website

You are now connecting to a website that is neither owned nor under the control of Viatris. Viatris is not responsible for the content of this site or any further links.
Please press OK to proceed or BACK to return to the Creon® patient website.
BACK
OK

Viatris UK Healthcare Limited (company registration number 09189103), an English company with a registered office address at 20 Station Close, Potters Bar, Hertfordshire, EN6 1TL (VAT - 421 623 781).

CRE-2022-0120 May 2023

Copyright © 2023 Viatris Inc. All rights reserved.

This website is owned and managed by Viatris. For more information visit viatris.co.uk.